The Canon V1 might be the most significant camera of the year – not just for Canon, but for the whole industry ...
Now in stock. The Canon EOS R1 is a sports or photojournalist's dream camera built for speed and precision this camera ...
6d
Digital Camera World on MSNCanon's new grips for the EOS R5 Mark II are ridiculously expensive, but are they worth the money?!The new Canon EOS R5 Mark II has not one, but three official Canon battery grips made specifically for it. So is the Canon BG ...
The A1 II is Sony’s best mirrorless camera yet, but it lacks innovation and video performance lags behind rivals.
Photography enthusiasts pay a lot for their very powerful cameras. How much more should they pay to put them to much, much easier work as a webcam? However many hundreds of dollars you paid, Canon ...
12d
Digital Camera World on MSNThe uncrowned king: the Canon PowerShot G5 X Mark II was Canon's answer to the Sony RX100 lineOften overlooked, the Canon PowerShot G5 X Mark II was a powerful compact camera with a big sensor and a BIG zoom ...
Should you already happen to have a collection of Canon lenses, you might also consider this that drops the camera to $2,000 from $2,500.
If you want the best image quality from a mirrorless or DSLR camera, full-frame is the way ... as well as stills-first models including the Canon EOS R5 II. Our pick of the bunch is the Sony ...
17d
Hosted on MSNCanon R5 Mark II review: One camera to do it allCameras, once considered essential, have evolved into specialised tools. But in 2025 if you need one, irrespective of your requirement, chances are that you won't find a camera better than the Canon ...
Combining a large sensor with rapid burst speeds, cutting-edge autofocus and often powerful video performance, the top options from the likes of Canon ... find the ideal camera for what you ...
Check out our Canon EOS R7 review for further details. This camera is a jack-of-all-trades and is $770 off, it will consistently deliver results whether you're shooting video or stills and boasts ...
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results